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Qbjectives. A multicenter study was carried out to evaluate the 
efficacy with which SHU 508A enhances left heart Doppler signals 
and improves the clinical quantification of valve disease. 
8ockground. Poor signal-to-noise ratio often limits the Doppler 
interrogation of left heart tiows. This problem may be resolved by 
the enhancement of Doppler signals by an ultrasound contrast 
agent capable of pulmonary transmission, such as the recently 
developed SHU 508A. 
Methods. Left heart contrast enhancement was tested for 1) 
continuous wave Doppler evaluation in 51 patients with aortic 
stenosis, 2) pulsed Doppler transthoracic evaluation of pulmo- 
nary ~nous flow in 85 patients, and 3) colnr Doppler evaluation 
of mitrsi regurgitation in 60 patients. Studies were performed 
immediately before and during the intravenous administration of 
SHU 508A (16 ml of 200 m&n!) and compared with unenhanced 
transesophageal data in represeniative subsets of patients. 
Results. ‘WU 508A had no serious adverse effecls. A significant 
increase in Eeft heart Doppler signal intensity lasted for 3F to 
300 s. The continuous wave Doppler velocity envelope was en- 
hanced for all jets, but Doppler peak velocity was not altered in 
- 
Doppler echocardiography allows the noninvasive assessment 
of normal and pathologic intracardiac flow and the accurate 
determination of intracardiac velocities and pressure gradi- 
ents. Its value has been widely accepted in clinical cardiolo,y. 
However, the diagnostic accuracy of the Doppler technique 
depends, in part, on the quality of Doppler recordings. The 
actual display of intracardiac flow is limited, particularly in 
strlrctures more remote from the transducer, such as the atria, 
because of increased absorption and scattering of ultrasound. 
The color Doppler modality in particular is subject to these 
limitations and has, so far, led the cardiologist to accept the 
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high quality baseline studies. However, Doppler contrast enhance- 
ment resulted in higher measured peak gradients (p < 8001) in 
29 patients with aortic stenosis who had poor quality baseline 
studies. This improved the overall correlation tith invasive 
pressure measurements (r = 0.73 vs. r = 0.89, p < 0.31). The 
enhanced pulsed Doppler traces of transthoracic pulmonary 
venous flow allowed quantitative analysis in 92% patients (vs. 27% 
at baseline) and correlated well with peak velocities and velocity 
profiles obtained by transesophageal echocardiography (r = 0.91, 
p < 8.001). The enhanced color Doppler display of regurgitant jets 
increased jet area with a high interindividual variability (mean 
276%), resulting in almost identical jet areas as unenhanced 
transesophageal values (r = 0.97, p < 0.001). 
Conclusions. SHU 508A is a safe transpulmonaty contrast 
agent that significantly enhances both spectral and color Doppler 
signals in the left heart. In specific patient subsets, the increase in 
signal-to-noise ratio improved the quantitative assessment of 
aortic stenosis, pulmonary venous flow and mitral regurgitation. 
(J Am Co11 Cardioi 1995;25:500- 8) 
reduced sensitivity of flow detection as “normal.” However, 
cardiac cavities are full of flowing blood and should be 
displayed in full color by the color Doppler technique if this 
technique is supposed to mirror reality. Efforts to compensate 
for the apparent loss of diagnostic flow information have fed to 
the acceptance of transesophageal Doppler echocardiography 
in clinical routine. An alternative method of compensating for 
reduced precordial Doppler sensitivity is to enhance the rela- 
tively low intensity Doppler sigrr!s by contrast agents, a 
method that has been reported ’ Jrn both experimental and 
human studies (1-4). However, this augmentation has previ- 
ously been limited to the right heart chambers (5). Preliminary 
results for Doppler contrast enhancement of tire left cardiac 
chambers using intravenous injections have recently been 
reported (h-8). 
The present investigation was designed as a multicenter 
clinical study to systematically evaluate the potential clinical 
role of Doppler contrast enhancement for the evaluation of 
aortic stenosis, pulmonary venous flow and mitral regurgitation 
and to assess the efficacy and patient tolerance of SHU 508A. 
The results of contrast-enhanced Doppler techniques were 
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TaL;:e 1. Exclusion Criteria for Phase Ill Mu!ticenter Clinical Study 
With SHU 508A __- 
Galastosemia 
Critically il l patients (e.g., <? wk after myocardial infarction, life-threatening 
arrhythmia. severe heart failure) 
Patient< in whom drug therapy or radiorherapy might initiate a change in 
chemxal laboratory variables 
Patients who had an angiographic study within 24 h 
Paiients with mental retardation 
Petients who had pa.tiiipated in another drug study within 30 days of the 
present one 
Pregnant or lactating women 
also compared with those of transesophageal technique in a 
selected patient subset. 
Methods 
This study was carried out as a prospective multicenter 
collaborative study in five European cardiology centers under 
the auspices of the Levovist Cardiac Working Group and as a 
subsection of a European multicenter phase III clinical study. 
Before the investigations began, the study protocols were 
approved by the individual institutional review boards of the 
participating institutions (established according to the Food 
and Drug Administration guidelines). 
Study patients. Patients of either gender were invited to 
participate in the study if they met the following inclusion 
criteria: a suboptimal precordial Doppler study of left-sided 
cardiac flows and age 218 years. Because of the intrinsic 
sensitivity problems of color Doppler, almost every patient 
entering the echocardiographic laboratory had ~70% of the 
left atrium color coded from normal anterograde flow and thus 
proved eligible for the study. Patients were excluded from tht 
study if they met the criteria shown in Table 1. One hundred 
fifty-two patients (90 men, 62 women; mean age 59 years, range 
23 to 90: mean weight 72 2 12 kg, mean height 169 2 9 cm) 
were studied between June and December 1992. Sinus rhythm 
was present in 121 patients, and atrial fibrillation in 31. 
Native or prosthetic valvular aorfic stenosis was evaluated in 
51 patients. Mixed native aortic valve disease was present in 12 
of these patients. Six patients with an aortic valve prosthesis 
were inciuded. Correlative invasive pressure measurements 
were performed in 24 of these patients. Pulmonary venousfiOw 
was assessed in 85 patients. These included patients with mitral 
valve disease (n = 20), mitral valve prosthesis (n = 7), aortic 
valve disease (n = 4), aortic valve prosthesis (n = 6), ischemic 
heart disease (n = 28), hypertensive heart disease (n = 2), 
dilative cardiomyopathy (n = 7) and 10 clinically normal 
subjects. Sinus rhythm was present in 64 patients, atrial 
fibrillation/flutter in 20 and paced rhythm (WI mode) in 1. 
Immediately before the transthoracic contrast study, trans- 
esophageal echocardiography was performed in 13 patients, 12 
of whom had atrial fibrillation. 
A4ilral regurgitation was evaluated in 60 patients. Mitral 
valve prosthesis was present in 14 patients, mixed mitral valve 
disease in 5, isolated regurgitation in 12, ischemic heart disease 
in 18, dilative cardiomyopathy in 4 and aortic valve stenosis or 
prosthesis, or both, in 7. On the basis of clinical indications, a 
left ventricular angiogram was performed in 23 of these 
patients within 3 days of the ultrasound study and was used to 
grade the severity of mitral regurgitation according to the, 
classification of Nagle et al. (9): 0 = none; 1 = mild; 2 = 
moderate; and 3 = severe. Transesophageal Doppler echocar- 
diography was performed for clinical reasons in 14 patients just 
before the transthoracic contrast study. 
Study protocol. After the patients had signed the informed 
consent form, they underwe& a baseline clinical evaluation 
consisting of medical history, physical examination, electrocar- 
diogram (ECG), biochemical screen and a blood count. This 
ciinical evaluation was repeated 0.5 and 24 h after the contrast 
study. Pulse rate and blood pressure were measured at baseline 
and 5 min after each contrast injection. Continuous ECG 
monitoring was maintained during the contrast study. Patients 
were monitored for the development of adverse symptoms 
during the test period and immediate follow-up period and 
were questioned about the presence of side effects or subjec- 
tive complaints during and after the contrast study. 
Injection of SHU 50% The contrast agent SHU 508A is a 
suspension of galactose microparticles (median. diameter 
2 pm) in water that is prepared 2 min before injec!ion by 
adding sterile water to the vial with 4 g of galactose particles: 
17 ml water for a concentration of 2i;!l mg microparticleslml, 
it ml for 300 mglml and 8 ml for 400 mgiml. Each patient 
received 16 ml of SHU 508A, with 200 mglml as standard dose. 
If modified doses were required according to the degree of 
contrast enhancement in the individual patient, the dosage 
could be reduced (10 ml of 200 mg/ml) or increased (10 ml of 
300 mg/ml or 8 ml of 400 mglml). Injections could be repeated 
only 5 min after the contrast effects had completely disap- 
peared. Up to six injections were possible if diagnostically 
*equired. The contrast agent was injected at a rate of 1 to 
2 ml/s through a 20-gauge cannula positioned in an antecubital 
vein, followed by a 5-ml flush of saline soluticn. 
Doppler examination. Transthoracic Doppler echocardi- 
ography was performed at baseline before the first injection of 
SHU 508A and for 10 min after each contrast injection, using 
commercially available ultrasound devices (Acuson 128 XPIO, 
Hewlett-Packard 1000, Toshiba SSH 270 or Vingmed 750). 
Examinations were performed with the use of Z- to 2.5”MHz 
transducers. Optimized setting of filters, puise repetition fre- 
quency and gain for the individual Doppler studies were kept 
constant during the study. Color, continuous wave and pulsed 
Doppler were used as clinically appronrrate for the individual 
cardiac lesions. All studies were stored on VHS videotape for 
off-line analysis by two independent observers. Transesopha- 
geal studies were performed in a standard manner using 
~-MHZ imaging. 
Measurements. The duration of diagnostically usable sig- 
nal intensity increase within the left-side heart chambers was 
assessed in seconds. Anterograde je!s from aortic stenosis and 
retrograde jets from mitral regurgitation were recorded by 
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Figure 1. Original continuous wave 
Doppler of anterograde aortic flow 
vdodi~s 1: a patient with aortic 
steno&. Left, Baseline recording 
har! a vague envelope. Right, Con- 
trust enhancement provided a clear 
envelope and allowed confident 
measurement of peak velocity. 
continuous wave Doppler for the measurement of peak veloc- 
ity and the calculation of the peak gradient, using the simpli- 
fied Bernoulli equation. Pulsed Doppler recordings of the 
pulmonary venous flow from the right upper pulmonary vein 
were analyzed for the peak velocities and velocity-time inte- 
grals of anterograde flow during systole and diastole, for the 
duration of the retrograde flow during atria1 contraction and 
systolic reversed flow from mitral regurgitation. In the four- 
and two-chamber views, the color Doppler frames with the 
maximal jet area of mitral regurgitation were selected for 
planimetry of these areas of disturbed flow (coded as turbu- 
lence plus immediately contiguous blue). Cavity area was 
measured from the same frame to allow calculation of jet area 
as a percent of cavity area. Color Doppler and spectral 
Doppler signal intensity was graded from 0 to 5 (0 = no flow 
detected; 1 = scarce signals; 2 = weak signals; 3 = moderate 
bignais; 4 = good signals; 5 = signals too strong or artifactual) 
as previously described (4,8). 
Statistical analysis. Differences in data obtained in indi- 
vidual groups were assessed using nonparametric tests. These 
were the Wilcoxon signed-rank test and the Friedman test for 
paired data. The differences were considered significant if 
p < 0.05 for two-tailed testing. Results are presented as mean 
value 2 SD in text and tables. Simple linear regression analysis 
wds used to correlate ttansesophageal with transthoracic con- 
trast-enhanced measureme,&. The effect of contrast enhance- 
ment on the correlation between Doppler and catheter-derived 
peak gradients or mitral regurgitation jet area and angio- 
graphic degree of severity was tested by multiple regression 
analysis. 
Results 
Patient toleraace. In the course of the study, heart rate, 
blood E KL’“V and the ECG did not change. There were no I... 
clinically relevant changes in blood chemistry or the complete 
blood count. Eight patients (5%) mentioned a brief burning 
sensation at the injection ,site; itvo (1.3%) had transient 
headache; and one (0.7%) had taste sensations. There were no 
serious adverse events. 
D/)se and duration. In 50% of the patients, the initial 
dosage of SHU 508A for Doppler enhancement (16 ml of 
200 mg/ml) provided good quality images. In the remaining 
patients, 60% requi d 10 ml of 300 mg/rnl for better images; 
10% requneo 8 ml 200 mglml; and in 30% of the patients a 
reduction to 10 ml 100 mg/ml was required. 
Mean duration of significant signal intensity increase was 
120 s (range 30 to 300) for color Doppler, 140 s (range 30 to 
300) for pulsed Doppler and 100 s (range 30 to 180) for 
continuous-wave Doppler. 
.4ortic stenosis. Signal intensity of continuous-wave Dopp- 
ler recordings increased significantly in the anterograde jets of 
aortic stenosis after injection of SHU SOSA (score 3.8 2 05 vs, 
2.3 t 1.1, p < 0.001) (Fig. 1). In only two patients was there 
hardly any contrast enhancement effect on the poor quality rest 
velocity envelopes. In the subgroup of patients with good 
quality baseline studies (score 3 and 4) (n = 22), peak jet 
velocity and peak gradient did not change after contrast 
injection. In the patients with ambiguous envelopes at baseline 
(score 0 to 2) (n = 29) peak gradients after contrast en1a -*- 
ment significantly increased by 2 to 88 mm Hg (mean 
26 mm Hg, p < 0.001) (Fig. 2). Thus, the correlation with 
invasive pressure measurements improved (p < 0.01) from r = 
0.73 before to r = 0.89 with contrast enhancement (Fig. 3). 
Pulmonary venous flow. When color Doppler was used in 
the four-chamber view, pulmonary venous i&w into tine left 
atrium was clearly visualized after contrast enhancement so 
that the sample volume of pulsed Doppler could be accurately 
placed for recording pulmonary venous flow velocities. Pulsed 
Doppler flow envelopes improved (Fig. 4) in all patients after 
intravenous SHU 508A (score 3.1 2 0.8 vs. 1.7 2 1.1, p < 
0.001). At baseline study, quantitative assessment of systolic 
and diastolic flow velocities was possible in 23 (27%) of 85 
patients and after contrast enhancement in 78 (92%). In the 
former group of patients, the duration of atria1 reversal did not 
change after contrast enhancement, but systolic and diastolic 
indexes increased after Doppler enhancement if baseline sig- 
nal intensity was <3 (Table 2j. These indexes remained 
unchanged in those patients with good baseline signal intensity 
(score 23). Of the seven patients with persisting poor quality 
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clear envelope vague envelope 
before injection of SHU SOBA 
Figure 2. ApparelIt difference in peak Doppler gradients between 
recordings before and after intravenous injection of SHU 508A (Peak 
gradient,,,, iOXA - Peak gradient,,,,,,,,). Recordings were differenti- 
ated with regard to baseline quality as clear envelope (score 3 and 4) 
or vague envelope (score 0 to 2). Significant increase in peak gradient 
was observed in the vague envelope subgroup only. 
of image after contrast enhancement, four had a mitral valve 
prothesis. Reversed systolic flow, indicating severe mitral 
regurgitation (four patients), could be recorded in one patient 
at baseline study and in four of four after contrast enhance- 
ment. Peak systolic and diastolic pulmonary flow velocities 
after contrast enhancement were in accordance with trans- 
esophageal Doppler measurements (r r 0.91) (Fig. 5). 
Mitral regurgitation. In color Doppler, maximal jet area of 
mitral regurgitation (Fig. 6) increased from 3.1 c 3.4 cm* at 
baseline to 9.5 2 9.2 cm’ with contrast enhancement (p < 
0.001). There was a high degree of variability in the increase of 
jet area in individual patients ranging between 0% and 1,400% 
of the baseline jet area (mean 276%). The correlation behveen 
transesophageal measurements of maximal jet area and trans- 
thoracic measurements was moderate for the baseline images 
(r = 0.71) demonstrating underestimation for the unenhanced 
transthoracic Doppler images, and was excellent after contrast 
enhancement (r = 0.97) with the individual values close to the 
line of identity (Fig. 7). The individual jet areas expressed as a 
perceilt of left atrial area were compared with the angiographic 
grading. After contrast enhancement, discrimination of sever- 
ity grades improved (p < O.OOS), and the correlation coefficient 
was r = 0.90 compared with r = 0.76 at baseline. 
The unenhanced continuous wave Doppler recording of re- 
gurgitant jet velocity had ambiguous envelopes in 23 patients. 
After contrast enhancement (Fig. S), signal-to-noise ratio im- 
proved so that peak velocity could be confidently measured in 17 
(4.3 -t 1.0~~. 3.2 ? 1.0 m/s at baseline, p < 0.01). In the remaining 
patients with good quahty baseline studies, the iepi&Bi jet 
velocities were also enhanced, but without significant change of 
peak velocity (5.3 -C 0.4 vs. 5.0 c 0.3 m/s at baseline). 
SEE=Z0.9 mmHg 
0 20 40 60 80 100 120 140 mm 
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mmHg 
80 100 120 140 
-was1 e peak to peak gradtent 
Figure 3. Correlation between invasive peak gradient (horizontal) and 
Doppler peak gradient (verticali at baseline study was moderate (top 
panel) and improved with contrast enhancement (bottom panel). 
Dotted lines = SEE. 
Discussion 
Patient toler,ntce. SHU 508A is composed of a combina- 
tion of galactose (99.9%) and palmitic acid (0.1%). Previous 
studlet !n 1,500 patients on the safety of this contrast agent 
have reported a low incidence of adverse events and no serious 
adverse reactions (8,lO). The reactions noted in the present 
multicenter study are most probably attributable to local 
effects caused by the hyperosmolarity of the galactose suspen- 
sion. They were brief and resolved spontaneously. No clinically 
relevant changes in laboratory variab!es or hemodynamic and 
physical signs were detected. On the basis of these data, it 
would appear that the intravenous administration of SHU 
508A is safe and ~11 tolerated by patients. 
Dose. In normal subjects, there is high interindividual 
variation in the echogenicity of the flowing blood and in the 
amount of ultrasound absorption by precordisl t&tic. ?-us, it 
is not surprising that the concentrations of SHU 50SA required 
for good quality Doppler enhancement varied between 200 
and 400 mgiml in the present study. The present data indicate 
that the initial dose of SHU 5tBA should be 16 ml (200 mglml). 
If there is still insufficient color coding of normal anterograde 
atria1 flow (~70% of the left atrial area), an increase in the 
concentration of subsequent injections is warranted to 
300 mglml and then to 400 mglml. If artifacts are noted, a 
reduction in dosage to 10 ml of 200 mg/ml coupled with a 
slower injection rate is advisable. The duration of increased 
Doppler signal intensity by the contrast agent was long (range 
3G to 300 s) and allowed optima1 placement of the sample 
volume in each patient. In contrast, sonicated serum albumin 
has been reported to provide 10 to 90 s of Doppler signal 
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Figure 4. Original pulsed 
Doppler rerording of pul- 
monary venous flow from an 
apical transducer position. 
Left, Note the signal-to- 
noise ratio preventing any 
quantitative analysis. Right, 
Whh contrast enhancement 
the signal-to-noise ratio im- 
proves, and flow traces have 
clear envelopes. 
increase (6,7). The duration tif tbc contrast effect in two- 
dimensional echocardiograpkj of SHU 509A has been reported 
to be shorter than that for color Doppler enhancement (ll), 
indicating the high sensitivity of Doppler for contrast euhance- 
ment at even low concentrations of the microbubbles, which may 
hardly- be perceived in two-dimensional echocardiography. 
Aortic stenosis. Recently, a study in a small group of 
patients selected for poor quality Doppler images reported (6) 
that injection of sonicated albumin microbubbies @as useful 
for the noninvasive assessment of severity of aortic 5;escrsk. 
Our study group included 51 unselected patients with aortic 
stenosis as a component of their cardiac lesions. After intra- 
venous injection of SHU 508A, the envelope of aortic flow 
velocity was enhanced in 95% of the patients, enabling the 
calculation of the pressure gradient with certainty, as con- 
firmed by good agreement between Doppler and catheteriza- 
tion data in a subset of patients. Low Doppler signal intensity 
of the aortic vdocity curve caused poor quality recording in 29 
of 51 patients at basal conditions, so that pressure gradient 
could not be measured confidently. In 15 of these patients, 
marked Doppler underestimation of actual pressure gradient 
occurred in the absence of contrast enhancement. Now, it must 
be emphasized that the apparent increase in peak flow velocity 
after intravenous injection of SHU 508A is solely a result of an 
increase in the signal-to-noise ratio and of the fact that 
low-intensity Doppler signals of any velocity were misinter- 
preted as noise and therefore were not displayed as velocity by 
the ultrasound machine. This is confirmed by our data in the 22 
patients with good quality Doppler recordings at baseline 
study, in whom peak velo&y did not change after injection of 
the contrast agent. 
Pulmonary venous flow. Transthoracic recording of puhno- 
nary venous flow is limited, particularly in patients with 
cardiomegaly or large atria. Our success rate of recording 
adequate pulmonary venous flow patterns from at least one 
pulmonary vein was only 27% in unselected patients with 
valvular and left ventricular diseases undergoing baseline 
echocardiography. There are few published reports about the 
success rate with which pulmonary venous Row can be re- 
corded from the precordium. Only two reports (K&13) exist in 
which a higher percent of pulmonary vein flow was recordable. 
These were related either to patient selection or to the 
investigators having extensive experience in the field of Dopp- 
ler. Contrast enhancerrz: improved the signal-to-noise ratio 
Table 2. Comparison of Unenhanced and Contrast-Enhanced Transthoracic Doppler Indexes of Pulmonary Venous Flow in the Subgroup of 
23 Patients in Whom Unenhanced Pulsed Doppler Recordings Could Be Analyzed 
~-_ 
Signal intensity (score O-5) 
Max systolic velocity (cm/s) 
Systolic velt 3ity time 
integral (cm; 
Max diastolic velocity (cmis) 
Diastolic velocity time 
integral (cm) 
Max velocity atrial 
reversal (cm/s) 
Duration atrial reversal (ms) 
All (n = 23) B Signal Intensity ~3 (II = 8) 
P 
B C Value 
P 
B c Value 
2.5 _+ 0.6 3.6 IT 0.7 < om 
‘6i 2 14 53 C 36 NS 
15.1 r 5.9 15.4 z 9.9 NS 
sfJ+ 11 62 2 12 < 0.05 
12.6 + 4.5 14.9 t- 4.4 < 0.05 
28 + 8 3129 NS 
147 2 50 152 2 50 NS 
3.0 t 0 4.0 % 0.5 < 0.001 
68~13 71 -e 13 NS 
19.2 + 3.8 20.9 C 5.4 NS 
57 It 10 572 11 NS 
14.6 r 3.9 14.8 2 5.5 NS 
31 c9 32 +_ 8 NS 
172 + 46 179 t 50 NS 
B Signal Intensity ~3 (II = 15) 
P 
B C Value 
2.0 2 0.6 3.4 I 0.7 < 0.001 
46 f 32 50 z 38 < 0.05 
12 1 r 5.7 13.4 i: 10.1 NS 
55 % 15 632 11 c 0.01 
10.4 lr 4.6 15.1 2 3.3 < 0.01 
14 + 26 18229 < 0.05 
135 2 49 140 If. 51 NS 
Data presented are mean value t SD. B = unenhanced baseline; C -I contrast enhanced; max = maximal. 
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Figure 5. Top panels, Peak systolic (A) and diastolic (B) 
pulmonary flow velocities by contrast-enhanced transthoracic 
(‘II%) pulsed Doppler (vertical) plotted against the corre- 
sponding peak velocities obtained with unenhanced trans- 
esophageal (TEE) Doppler. Bottom panels, Agreement be- 
tween the two techniques for measuriug peah pulmonary flow 
velocity. diff. = difference. 
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average pulmonary venous diastolic velocity by TEE and enhanced TTE 
and thus the Doppler envelopes in almost all patients, with the 
possible exception of these with mitral valve prostheses. Con- 
trast enhancement allowed quantitative analysis of pulmonary 
venoJs ,“lsw in 92% of our patients. The indexes derived from 
the enhanced recordings were confirmed by the data derived 
from high quality baseline studies (Table 2). It mast be 
emphasized that analyzable but weak signals with complete 
envelope resulted in underestimation of the most frequently 
measured indexes, such as maximal velocities and time-velocity 
integrals. Evaluation of pulmonary venous flow patterns with 
regard to their diagnostic and hemodynamic relevance has 
mainly been performed with transesophageal echocardiogra- 
phy (14,15). We therefore compared measurements of peak 
flow velocities as obtained from transesophageal echocardiog- 
raphy with contrast-enhanced transthoracic velocities and 
found good dgreement (Fig. 5). Our results indicate that 
contrast-enhanced Doppler provides similar information, thus 
obviating the need for transesophageal echocardiography in 
the majority of patients. 
Mitral rzgwgitation. The mean increase in mitral regurgi- 
tation jet area as displayed by color Doppler was 276% with 
high interindividual variation. These results are similar to 
those of a recent two-center study (8). It is our opinion that 
there is persistent reluctance among cardiologists to accept the 
contrast-enhanced display as a Clhicdl tool simply because 
many years of low signal intensity transthoracic imaging have 
made the image of a mainly black-coded left atrium so familiar. 
We therefore compared transthoracic jet areas before and 
Figure 6. Original color Dopp- 
ler recording in a patient with 
severe mitral regurgitatiorS as 
a result of prolapse of the pos- 
terior leaflet. Note the com- 
plete display of the eccentric 
jet only on the right tracing 
with contrast enhancement. 
LA (RA) = left (right) atrium; 
LV (RV) = left (right) ventri- 
cle; liMi(i = day. 
cm 2 
0 10 20 30 40 50 
transoesophageal colour Doppler 
cm2 
20 
10 --- Mean + 2 50 
. 
0 r-s-- . - Mean 
l * . -10 i ----- Mean - 2 so 
. 
-20 . . . . . . . . , an2 
0 5 10 15 20 25 30 35 40 45 50 
average jet area by TEE and enhanced ‘ITE 
Figure 7. Top, Maximal jet area of mitral regtirgnatior as obtained 
with transthoracic color Doppler (TIE) (vertical) betore (cpes cir- 
cles) and after (closed circles) contrast enhancement plotted against 
maximal jet area obtained at transesophageal color Doppler (TEE) 
(horizontal). Dashed liae = curve of equality. There is obvious 
underestimation by the unenhanced trans&horAs method. Bottom, 
Agreement between contrast-enhanced transthoracic and unenhanced 
transesophageal measurements is demonstrated. 
Figure 8. Original continu- 
ous wave Doppler recording 
of the regurgitant velocities in 
mitral regurgitation is too in- 
distinct to determine peak ve- 
locity at the baseline study 
(left). After contrast enhance- 
ment (right), the increased 
intensity of Doppler signal 
provided clear envelopes and 
therefore quantitative analysis. 
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Table 3. Comparison Between Patients bith am3 Without 
Transesophageal Echocardiography or Left Ventricular Aneiography - 
Mitral Reyrgitarion ,lortic Strnoais 
Jet Area Peak Ciradient 
No. of 
( ‘,T LA) 
No. of 
(mm Hgl 
P& B C Pi, B c 
LV angiography 
With 23 13" IO 37 r 23 24 55 232 74 z 29 
NS NS NS NS 
Without 37 121-16 35227 27 44 IL 37 60 i- 45 
TEE 
With 14 12 2 12 2’1 + 27 
NS NS 
Without 46 13% I’ 36 i 24 
Data presented are mean value 2 SD LA = left atrium; LV left 
ventricclar; Pts = patienis: TEE = transesophageal echocardiography; other 
abbreviations as in Table 2. 
after contrast enhancement with the better accepted images 
from the transesophageal approach (which is well ‘mown for its 
higher sensitivity in the detection of flow). Recent .;tudies have 
shown that jet areas displayed transesophageally are consider- 
ably larger than those shown transthoracically (16,17), and 
semiquantification has been proposed using transesophageal 
imaging (18). The data in this study confirmed gross underes- 
timation of jet areas displayed by the transthoracic approach 
compared with the transesophageal approach (Fig. 7). How- 
ever, contrast-enhanced jet areas were virtually the same size 
as those displayed with transesophageal imaging. This is sur- 
prising because the two imaging modalities differ with respect 
to the most important factors that influence the sensirivity of 
flow detection by color Doppler flow imaging. These are 
attenuation due to ultrasound penetration depth and absorp- 
tion from precordial tissues, both of which are severe handi- 
caps in transthoracic color Doppler display, whereas the higher 
ultrasound frequency used with the transesophageal approach 
is known to reduce jer area in the presence of low Doppler 
signal intensity (19). It appears from our data that ultrasound 
penetration depth and precordial absorption are dominant 
limitations of unpredictable extent for the transthoracic display 
of regurgitant jet velocities in the unenhanced setting with low 
Doppler signal intensities. Doppler signals too low in intensity 
are obviously misinterpreted as noise by the ultrasound ma- 
chine and are cut off by the wall filter. However, this limitation 
can be overcome by using contrast agents to increase the 
echogenicity of blood, and hence Doppler signal intensity, thus 
allowing all Doppler flow information to be displayed. It 
therefore follows th;: rising this compensation technique im- 
proves the correlation between jet area and angiographic 
grading of severity in mitral regurgitation to the level we have 
hitherto attributed solely to the transesophageal technique, as 
we have shown in the present study. 
Clinical implications. Contrast-enhanced Doppler allilws 
confident evaluation of severity of aortic stenosis and mitral 
regurgitation even in technically difficult cases. This technique 
further faciiitates assessment of pulmonary venous fiow pat- 
tein and thus the scmiquantifi&ion of mitral regurgitation, 
which has her-tofore been ttie domain of transesophageal 
echocardiography. tiecause of patient discomfort associated 
with the transesophageal tech.ique, Doppler contrast en- 
hancement ROW appears fo be an important new alternative in 
the sequence of diagnostic tools used to assess mitral regurgi- 
tation. Furthermore, contrast enhancement facilitates im- 
proved recordings of the maximal mitral regurgitant jet veloc- 
ity by continuous wave Doppler. This may have potential with 
regard to calcula:ion of maximal instantaneous first derivative 
of left ventricular pressure for additional evaluation of left 
ventricular function (20). 
In our opinion patients should receive an ultrasound con- 
trast agent if the spectral Doppler recordings essential for 
quantification of the inditriduai lesion are suboptimal for 
analysis. For evaluation of regurgitant lesions it is essential that 
flow detection be sensitive enough in the receiving chamber. 
This may easily be assessed by using normal anterograde flow 
as an indicator of color Doppler sensitivity. If the color-coded 
area of normai iiow is ~70% of this particular cavity, Doppler 
signal enhancement is recommended. 
Study limitations. We did not perform simu!taneous 
Doppler and catheterization studies, Simultaneous trT%nsesoph- 
ageal and precordial contrast studies were not performed 
either but were performed one after the other during stable 
hemodynjmic conditions. The subgroups of patients with 
either angiqgraphic or transesophageai evaluation were not 
different wi,h regard to severity of cardiac lesion (Table 3). 
The dura!ion of ccmtrast enhancement was assessed by inspec- 
tion of the video recording and was therefore a subjective 
iudgment. This method zppenred to be acceptable because of 
the length of the time intervals observed. Similarly, the scoring 
of Doppler signal intensity for the assessment of image quality 
is subjective but has been shown to have acceptable interob- 
server and intraobserver variability (21). 
Summary. Peripheral venous injection of the galactose- 
based contrast agent SHU 508A enhances spectral and color 
Doppler in the left heart chambers, thus increasing the sensi- 
tivity of the Doppler system for displaying all flow information 
avaiiable from the patient. This has been shown to be partic- 
ularly useful in rhe evaluation of aortic stenosis and mitral 
regurgitation. This technique also allows better assessment of 
indexes of !efi ventricular function derived from pulmonary 
venous flow pattern and mitral regurgitant velocity envelopes. 
Thus, it can improve evaluation of valve lesions and their 
funciional hemodynamic consequences anti may obviate the 
use of transesophageal echocardiography in a significant num- 
ber of cases. 
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